Hala Adil
Dermatology · Saint Louis, MONPI 1235428582
Payments from drug & device makers
Across 411 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$942
- E.r. Squibb & Sons, L.L.C.$548
- Amgen$537
- Pfizer$511
- Incyte Corporation$366
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,80992%
- Education$4778%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 104 | $1,409 |
| Johnson & Johnson | 44 | $942 |
| E.r. Squibb & Sons, L.L.C. | 37 | $548 |
| Amgen | 42 | $537 |
| Pfizer | 32 | $511 |
| Incyte Corporation | 16 | $366 |
| Dermavant Sciences, Inc. | 50 | $332 |
| Regeneron Healthcare Solutions, Inc. | 9 | $308 |
| Lilly USA, LLC | 11 | $223 |
| Sanofi | 8 | $195 |
| Arcutis Biotherapeutics, Inc. | 13 | $152 |
| Galderma Laboratories, L.p. | 7 | $129 |
| UCB, Inc. | 4 | $126 |
| Sun Pharmaceutical Industries Inc. | 5 | $113 |
| Organon | 11 | $98 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Journey Medical Corporation | 6 | $70 |
| Mayne Pharma Commercial LLC | 7 | $60 |
| Merz North America, Inc. | 1 | $37 |
| Novartis | 1 | $22 |
| Botanix SB Inc | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$6,287 in reported general payments places this provider in the 65th percentile of 263 dermatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 19 | $69,271 |
| Fluorouracil | 43 | $3,485 |
| Clobetasol Propionate | 93 | $3,160 |
| Hydroxyzine Hcl | 97 | $2,033 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 18 | $1,771 |
| Ketoconazole | 124 | $1,550 |
| Doxycycline Hyclate | 54 | $971 |
| Metronidazole | 20 | $962 |
| Triamcinolone Acetonide | 73 | $601 |
| Mometasone Furoate | 29 | $328 |
| Cephalexin | 14 | $312 |
| Finasteride | 22 | $307 |
| Fluocinonide | 11 | $244 |
| Fluconazole | 19 | $210 |
| Spironolactone | 13 | $206 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Saint Louis
- Milan AnadkatSaint Louis$2.4M
- Brian KimSaint Louis$2.3M
- Elaine SiegfriedSaint Louis$2.2M
- Craig LeonardiSaint Louis$1.7M
- Amy MusiekSaint Louis$577K
- Ann MartinSaint Louis$512K
- Mary GeorgeSaint Louis$400K
- Duane DilworthSaint Louis$301K
- Jennifer FehlmanSaint Louis$235K
- Dee GlaserSaint Louis$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.